Hepatitis C in Patients With RenalDisease: A Deeper Dive Into the KDIGO Guideline
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30047
Abstract: 2035 with NAC at this point is insufficient to stop the progression of liver injury, in particular, because DAMP release may even precede the rise in plasma transaminases in some cases.(1) In addition to HMGB1,… read more here.
Keywords: deeper dive; kdigo guideline; dive kdigo; hepatitis patients ... See more keywords
Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT
Sign Up to like & getrecommendations! Published in 2018 at "Infection"
DOI: 10.1007/s15010-018-1136-2
Abstract: PurposeYKL-40 is a chitinase-like protein expressed in multiple tissues including liver and is reported as a fibrosis marker. This study aimed to determine whether YKL-40 could serve as a diagnostic marker for the assessment of… read more here.
Keywords: fibrosis; liver fibrosis; hepatitis patients; chronic hepatitis ... See more keywords
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
Sign Up to like & getrecommendations! Published in 2017 at "Antiviral research"
DOI: 10.1016/j.antiviral.2017.08.016
Abstract: Background&aims: With the introduction of DAA's, the majority of treated chronic hepatitis C patients (CHC) achieve a viral cure. The exact mechanisms by which the virus is cleared after successful therapy, is still unknown. The… read more here.
Keywords: without prior; hepatitis; treatment; hepatitis patients ... See more keywords
Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease
Sign Up to like & getrecommendations! Published in 2021 at "EClinicalMedicine"
DOI: 10.1016/j.eclinm.2021.101180
Abstract: Background Alanine aminotransferase (ALT) is the most commonly used serum biomarker for chronic liver diseases (CLDs) but may not accurately reflect hepatic disorders and easily underestimates hepatic fibrosis. The previously revised upper limit of normal… read more here.
Keywords: chb; hepatitis; biomarker; hepatitis patients ... See more keywords
Implementation of treatment recommendations for chronic hepatitis B in patients attending specialized hospital care in Denmark – a region wide study
Sign Up to like & getrecommendations! Published in 2020 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2020.1779803
Abstract: Abstract Objective: To evaluate implementation of national guideline recommendations on treatment initiation for chronic hepatitis B (CHB) in Denmark. Methods: Using DANHEP, a nationwide cohort of chronic hepatitis B and C patients attending specialized hospital… read more here.
Keywords: patients attending; treatment; hepatitis patients; study ... See more keywords
Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000011950
Abstract: Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Chronic hepatitis B (HBV) and C virus (HCV) infection causes liver cancer. This protocol is to provide the methods used to assess the… read more here.
Keywords: hepatocellular carcinoma; hepatitis; hepatitis patients; risk hepatitis ... See more keywords
Hypophosphatemia predicts a failure to recover from adefovir‐related renal injury after dose reduction in lamivudine‐resistant hepatitis B patients
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology Research"
DOI: 10.1111/hepr.12865
Abstract: In chronic hepatitis B patients receiving 10 mg adefovir, dose reduction is recommended when renal injury appears. However, recovery is not always achieved and markers that recommend switching to another antiviral agent are unknown. We… read more here.
Keywords: adefovir related; hepatitis patients; renal injury; dose reduction ... See more keywords
Randomized clinical trials towards a single‐visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG‐101 in chronic hepatitis C patients and long‐acting injectable GSK2878175 in healthy participants
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13282
Abstract: Single‐visit cures for chronic hepatitis C are lacking. We conducted two clinical studies towards the goal of developing a regimen for single‐visit cure. In a randomized, open‐label, Phase 2 study (RG101‐04), investigators enrolled 26 adult… read more here.
Keywords: gsk2878175; hepatitis; hepatitis patients; chronic hepatitis ... See more keywords
Comparison of acknowledged hepatocellular carcinoma risk scores in high‐risk hepatitis C patients with sustained virological response
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13829
Abstract: Hepatitis C patients with advanced fibrosis or cirrhosis are at high risk of developing hepatocellular carcinoma (HCC) even after sustained virological response (SVR). Several HCC risk scores have been developed but which one is most… read more here.
Keywords: high risk; hepatitis patients; risk; model ... See more keywords
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Molecular Hepatology"
DOI: 10.3350/cmh.2018.0029
Abstract: Background/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we… read more here.
Keywords: fibrosis; biomarker; hepatitis patients; serum ... See more keywords
Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?
Sign Up to like & getrecommendations! Published in 2018 at "Annals of hepatology"
DOI: 10.5604/01.3001.0012.7200
Abstract: INTRODUCTION AND AIM Hepatitis patients usually present with comorbidities and polypharmacy which increases risk of potential drug-drug interactions (pDDIs). We explored frequency, levels, predictors, and clinical relevance of pDDIs in hospitalized hepatitis patients. MATERIAL AND… read more here.
Keywords: pddis; drug interactions; hepatitis patients; drug ... See more keywords